ATE519780T1 - Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen - Google Patents

Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen

Info

Publication number
ATE519780T1
ATE519780T1 AT06841562T AT06841562T ATE519780T1 AT E519780 T1 ATE519780 T1 AT E519780T1 AT 06841562 T AT06841562 T AT 06841562T AT 06841562 T AT06841562 T AT 06841562T AT E519780 T1 ATE519780 T1 AT E519780T1
Authority
AT
Austria
Prior art keywords
compositions
insulin
zinc
producing
acylated insulin
Prior art date
Application number
AT06841562T
Other languages
English (en)
Inventor
Svend Havelund
Frantisek Hubalek
Helle Olsen
Ib Jonassen
Thomas Hoeg-Jensen
Anne Plum
Ulla Ribel-Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE519780(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE519780T1 publication Critical patent/ATE519780T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
AT06841562T 2005-12-28 2006-12-21 Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen ATE519780T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05113021 2005-12-28
PCT/EP2006/070104 WO2007074133A2 (en) 2005-12-28 2006-12-21 Compositions comprising an acylated insulin and zinc and method of making the said compositions

Publications (1)

Publication Number Publication Date
ATE519780T1 true ATE519780T1 (de) 2011-08-15

Family

ID=36888823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841562T ATE519780T1 (de) 2005-12-28 2006-12-21 Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen

Country Status (10)

Country Link
US (2) US20090074882A1 (de)
EP (2) EP2505593A1 (de)
JP (3) JP4808785B2 (de)
CN (1) CN101389650B (de)
AT (1) ATE519780T1 (de)
DK (1) DK1969004T3 (de)
ES (1) ES2371361T3 (de)
PL (1) PL1969004T3 (de)
PT (1) PT1969004E (de)
WO (1) WO2007074133A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
ES2575984T3 (es) * 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP2505593A1 (de) * 2005-12-28 2012-10-03 Novo Nordisk A/S Zusammensetzungen enthaltend acyliertes Insulin und Zink und Verfahren zur Herstellung dieser Zusammensetzungen
ATE482977T1 (de) * 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
KR101441444B1 (ko) * 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
KR101699370B1 (ko) 2006-09-22 2017-02-14 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
CN101674812B (zh) 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US8710000B2 (en) * 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
ES2430042T3 (es) * 2007-11-16 2013-11-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
EP2254905B1 (de) 2008-03-14 2016-12-14 Novo Nordisk A/S Proteasestabilisierte insulinanaloga
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2607003T3 (es) * 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
US20160243199A1 (en) * 2015-02-25 2016-08-25 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
WO2011141407A1 (en) * 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US20130331320A1 (en) 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
AU2012213432B2 (en) * 2011-02-01 2016-10-13 Novo Nordisk A/S Purification of insulin
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
WO2013153000A2 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
JP6262206B2 (ja) 2012-05-01 2018-01-17 ノヴォ ノルディスク アー／エス 医薬組成物
IN2015DN03795A (de) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
WO2015104311A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
EP3006045B3 (de) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
EP3495384A4 (de) * 2016-08-02 2020-02-26 Jiangsu Hengrui Medicine Co., Ltd. Acyliertes derivat von menschlichem insulin oder einem analogon davon
HUE055231T2 (hu) 2016-12-16 2021-11-29 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények
TWI740099B (zh) * 2018-02-01 2021-09-21 大陸商江蘇恒瑞醫藥股份有限公司 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法
BR112020023485A2 (pt) 2018-05-24 2021-03-30 Jiangsu Hengrui Medicine Co., Ltd. Métodos para preparar um precursor de insulina humana recombinante ou análogo da mesma, insulina humana recombinante ou análogo da mesma e análogo de insulina acilado
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP2022540862A (ja) 2019-07-12 2022-09-20 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
CN113045473A (zh) * 2020-03-18 2021-06-29 广东东阳光药业有限公司 制备长脂肪链二酸衍生物的方法及其应用
CN116583531A (zh) * 2020-11-27 2023-08-11 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
EP4361174A1 (de) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Acylierte insulinhaltige pharmazeutische zusammensetzung
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3907676A (en) 1970-07-28 1975-09-23 Novo Terapeutisk Labor As Process for purifying insulin
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4876322A (en) 1984-08-10 1989-10-24 Siemens Aktiengesselschaft Irradiation cross-linkable thermostable polymer system, for microelectronic applications
DE3562922D1 (en) 1984-08-17 1988-06-30 Bayer Ag Thermoplastic moulding masses with flame-retarding properties
DE3433367A1 (de) 1984-09-12 1986-03-20 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS61226115A (ja) 1985-03-30 1986-10-08 Mitsubishi Metal Corp 線条体押し出し機
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DE69019534T2 (de) * 1989-12-21 1995-09-21 Novo Nordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
DK45590D0 (de) 1990-02-21 1990-02-21 Novo Nordisk As
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
ATE227583T1 (de) 1991-12-20 2002-11-15 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
ATE204882T1 (de) 1993-09-17 2001-09-15 Novo Nordisk As Acyliertes insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (en) 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
BR9607647A (pt) 1995-03-17 1999-04-06 Novo Nordisk As Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
EP0938502B1 (de) 1996-07-11 2004-10-06 Novo Nordisk A/S Verfahren zur selektiven acetylierung
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2218622T3 (es) 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
WO1998042368A1 (en) 1997-03-20 1998-10-01 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
EP0969860B1 (de) * 1997-03-20 2002-07-17 Novo Nordisk A/S Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP1283051B1 (de) 1997-06-13 2006-06-14 Eli Lilly And Company Stabile Insulinformulierungen
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
PL195845B1 (pl) 1997-10-24 2007-10-31 Novo Nordisk As Rozpuszczalny w wodzie agregat pochodnych insuliny
EP1039920A4 (de) 1997-10-24 2003-05-28 Lilly Co Eli Mit fettsäuren acylierteinsulinanaloge
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CN1278737A (zh) 1997-11-12 2001-01-03 阿尔萨公司 减少多肽自结合的方法
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DK1121144T3 (da) * 1998-10-16 2002-09-23 Novo Nordisk As Stabile koncentrerede insulinpræparater til pulmonar indgivelse
ES2180511T3 (es) * 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
PT2130554E (pt) 1999-02-22 2012-11-19 Univ Connecticut Formulações de factor viii isentas de albumina
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP4624600B2 (ja) * 2001-06-08 2011-02-02 トヨタ自動車株式会社 焼結合金、その製造方法およびバルブシート
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP1545460A4 (de) 2001-12-20 2005-11-16 Lilly Co Eli Insulinmolekül mit zeitverzögerter wirkung
AU2003208316A1 (en) * 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
AU2003218635A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
ES2360182T3 (es) * 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
JP2006504772A (ja) 2002-10-29 2006-02-09 アルザ・コーポレーション 安定化された固体ポリペプチド粒子
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
EP1597367B1 (de) 2003-02-19 2010-07-07 Novartis AG In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
EP1454630B1 (de) * 2003-03-04 2010-10-20 The Technology Development Company Ltd. Injizierbare Insulinzubereitung mit Langzeitwirkung und Verfahren zur dessen Herstellung und Verwendung
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
PT2107069E (pt) 2003-08-05 2013-04-23 Novo Nordisk As Novos derivados de insulina
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
JP2007532096A (ja) * 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
ES2383691T3 (es) 2003-12-23 2012-06-25 Pharmacia Corporation Formulación líquida estable de hormonas de crecimiento
PL1740154T3 (pl) 2004-03-12 2009-11-30 Biodel Inc Kompozycje insuliny o ulepszonym wchłanianiu
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
DE602005022895D1 (de) 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
PT1778723E (pt) 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
ES2575984T3 (es) 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
JP4874989B2 (ja) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス 可溶性で安定なインスリン含有調合物
EP1838290A2 (de) 2005-01-21 2007-10-03 Alza Corporation Therapeutische peptidformulierung zur beschichtung von mikronadeln mit erhöhter stabilität und mindestens einem gegenion
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
CA2626357A1 (en) 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Intranasal administration of rapid acting insulin
EP2505593A1 (de) 2005-12-28 2012-10-03 Novo Nordisk A/S Zusammensetzungen enthaltend acyliertes Insulin und Zink und Verfahren zur Herstellung dieser Zusammensetzungen
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
MX2008013165A (es) 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
KR101441444B1 (ko) 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
WO2007135117A2 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
KR101699370B1 (ko) 2006-09-22 2017-02-14 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
EP2036539A1 (de) 2007-09-11 2009-03-18 Novo Nordisk A/S Stabile Formulierungen aus Amylin und dessen Analogen
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
ES2430042T3 (es) 2007-11-16 2013-11-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (de) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmazeutische Zusammensetzung mit AVE0010 und Insulin glargin
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
AU2012213432B2 (en) 2011-02-01 2016-10-13 Novo Nordisk A/S Purification of insulin
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
EP2798546B1 (de) 2011-09-13 2020-12-23 Novo Nordisk A/S Adaptives system zur optimierung eines arzneimitteldosierungsplans im laufe der zeit
WO2013153000A2 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
JP6262206B2 (ja) 2012-05-01 2018-01-17 ノヴォ ノルディスク アー／エス 医薬組成物
JP6755175B2 (ja) 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
EP3668892A1 (de) 2017-08-17 2020-06-24 Novo Nordisk A/S Neuartige acylierte insulinanaloga und verwendungen dafür

Also Published As

Publication number Publication date
US11167035B2 (en) 2021-11-09
EP1969004B1 (de) 2011-08-10
DK1969004T3 (da) 2011-11-28
US20090074882A1 (en) 2009-03-19
WO2007074133A3 (en) 2007-10-11
JP5026567B2 (ja) 2012-09-12
EP1969004A2 (de) 2008-09-17
CN101389650B (zh) 2012-10-10
CN101389650A (zh) 2009-03-18
JP2009522231A (ja) 2009-06-11
PL1969004T3 (pl) 2012-01-31
JP4808785B2 (ja) 2011-11-02
EP2505593A1 (de) 2012-10-03
PT1969004E (pt) 2011-11-25
JP2011006428A (ja) 2011-01-13
ES2371361T3 (es) 2011-12-30
WO2007074133A2 (en) 2007-07-05
JP2011121963A (ja) 2011-06-23
US20140328943A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
ATE519780T1 (de) Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
DE602007011171D1 (de) Zusammensetzung und Verfahren zur Herstellung von Steviolglykosiden
WO2007081978A3 (en) Modulators of hepatocyte growth factor / c-met activity
BRPI0414066A (pt) 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha
DE602005004241D1 (de) Geformte Haftverschlüsse und Verfahren zur Herstellung
DE602006009192D1 (de) Verfahren zur Herstellung von Dünnschichttransistoren mit Top-Gate-Geometrie
ATE469557T1 (de) Verfahren zur herstellung von avocadopulver
WO2008129358A3 (en) Oil producing microbes and methods of modification thereof
GB201215252D0 (en) Methods of producing organic products with photosynthetic organisms and products and compositions thereof
ATE536165T1 (de) Dentalabdruckmaterial mit rheologischen modifikatoren und verfahren zu seiner herstellung
DE602005008006D1 (de) Zusammensetzung auf basis von aliphatischem polyesterharz, formkörper aus aliphatischem polyesterharz und verfahren zur herstellung des formkörpers aus aliphatischem polyesterharz
EP2669379A3 (de) Pflanzen mit veränderten Wachstumseigenschaften und Verfahren zu ihrer Herstellung
HK1103333A1 (en) Process for the production of compositions containing ribonucleotides and their use as flavouring agents
ATE534618T1 (de) Neues verfahren zur herstellung therapeutischer verbindungen und zusammensetzungen, dadurch hergestellte verbindungen und zusammensetzungen und deren verwendung
DE602006006009D1 (de) Methode zur Herstellung von Acrylsäure
DE112007001034T8 (de) Temperatursonde und Verfahren zur Herstellung derselben
WO2004110376A3 (en) Ccr-2 antagonists for treatment of neuropathic pain
ATE496967T1 (de) Verfahren zur herstellung von einer aromatischen polycarbonat-harzzusammensetzung und geformter artikel daraus
IL144830A0 (en) Ribosomes structure and protein synthesis inhibitors
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
DE602004002549D1 (de) Zusammensetzung zur Herstellung eines organischen und isolierenden Filmes sowie der daraus hergestellte Film
DE502007000129D1 (de) Kontinuierliches Verfahren zur Herstellung von vernetzbaren Organopolysiloxanmassen
DE602005004520D1 (de) Farbanzeigevorrichtung und verfahren zur herstellung
EP1909809A4 (de) Verfahren und zusammensetzung zur behandlung von diabetes und seiner komplikationen
HK1112592A1 (en) Composition for reducing the exudation of serum proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1969004

Country of ref document: EP